Loading...
01/11 04:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects strong financial performance with improved operational efficiency and positive free cash flow, despite minor uncertainties in FDA timelines. Raised revenue guidance and optimistic growth in core and innovative channels, combined with strategic investments in innovation and market expansion, indicate a positive outlook. However, management's lack of clarity on some future plans tempers the sentiment slightly, but overall, positive elements outweigh the negatives, suggesting a positive stock price reaction.
Revenue $192.9 million, representing year-over-year growth of 31%. This growth was driven by record performance in Zio Monitor and Zio AT, primary care expansion, innovative health channels, and new EHR integrations.
Gross Margin 71.1%, an improvement of 230 basis points compared to the third quarter of 2024. This was driven by volume leverage and operational efficiencies, offsetting higher blended cost per unit from increased Zio AT product mix.
Adjusted Operating Expenses $141.4 million compared to $143.8 million in Q3 2024. Excluding a $32.1 million charge in Q3 2024, the increase was due to volume-related costs and investments for growth. Adjusted operating expenses as a percentage of revenue improved due to efficiency initiatives.
Adjusted Net Loss $2 million, or $0.06 per share, compared to $39.2 million, or $1.26 per share, in Q3 2024. This improvement reflects better operational performance and cost management.
Adjusted EBITDA $21.6 million, or 11.2% of revenue, compared to negative 13.5% in Q3 2024. Excluding IPR&D expenses, Q3 2024 adjusted EBITDA margin would have been 8.3%, showing a 300 basis point improvement year-over-year.
Free Cash Flow $20.0 million, marking the third consecutive quarter of trailing 12-month positive free cash flow generation. This reflects sustainable efficiencies and investments in growth initiatives.
Zio Monitor and Zio AT: Achieved record performance, contributing to a 31% year-over-year revenue growth in Q3 2025. Zio AT saw year-over-year unit growth more than double the corporate average.
Zio MCT: Submitted 510(k) filing for next-generation mobile cardiac telemetry solution with advanced features like 21-day wear and improved detection algorithms.
AI-driven solutions: Advancing AI prediagnostic and diagnostic pathways for sleep apnea and arrhythmia detection, with promising pilot results in identifying undiagnosed cardiac arrhythmias.
Primary care expansion: Strong progress in using Zio as a rule-in or rule-out tool for earlier intervention, improving patient outcomes and reducing specialist bottlenecks.
International expansion: Growth in Japan with 13 systems live and positive physician feedback. In Europe, strong growth in the U.K. private market and presence in 4 EU countries, supported by clinical evidence.
Innovative channel partnerships: 18 active partner accounts targeting large undiagnosed arrhythmia populations, with a healthy pipeline of additional partnerships under discussion.
EHR integration: 76 of the top 100 customers are EHR integrated, with 30 systems live on Epic Aura. EHR integration has led to a 25% increase in monitoring volume within 6 months of going live.
Operational efficiencies: Achieved gross margin improvement to 71.1% in Q3 2025, driven by volume leverage and operational efficiencies.
Free cash flow: Generated positive free cash flow for the first time on an annual basis, marking a significant milestone in financial sustainability.
AI and data-driven evolution: Partnership with Lucem Health to advance clinical AI capabilities, aiming to transition from a device-enabled service to a comprehensive digital health platform.
Adjacent market expansion: Exploring sleep apnea as a complementary market, leveraging clinical overlap with arrhythmia and cardiovascular disease.
Regulatory Challenges: The company faces potential risks related to FDA remediation expenses and the review process for new product submissions, such as the 510(k) filing for Zio MCT. These regulatory hurdles could delay product launches or increase costs.
Tariff Impacts: Tariffs on global imports are expected to negatively impact gross margins by approximately 50 basis points for the full year 2025, adding financial pressure.
Market Competition: Despite strong clinical evidence, the company faces competition from short-duration Holter and event monitors, which still represent a significant portion of the market. This could limit market share growth.
Economic and Operational Efficiency Risks: While the company is focused on driving productivity gains and improving efficiencies, there is a risk that these initiatives may not yield the expected results, potentially impacting profitability.
Supply Chain and Cost Pressures: Higher blended cost per unit due to increased Zio AT product mix could offset operational efficiencies, impacting overall profitability.
International Expansion Risks: Efforts to expand in Japan and Europe involve uncertainties, including the need for differentiated reimbursement and competition with local cardiac monitoring devices. These factors could hinder international growth.
Strategic Execution Risks: The company’s ambitious plans to scale AI-driven solutions and expand into adjacent markets like sleep apnea carry execution risks, including the ability to validate and commercialize these innovations effectively.
Revenue Guidance: iRhythm raised its full-year 2025 revenue guidance to $735 million to $740 million, representing 24% to 25% year-over-year growth. This includes expectations of continued strong volume growth and a low single-digit pricing tailwind.
Gross Margin Outlook: The company anticipates full-year 2025 gross margin to slightly exceed 2024 levels, with clinical operations and manufacturing efficiencies offsetting tariff impacts. Tariffs are expected to negatively impact gross margin by approximately 50 basis points for the full year.
Adjusted EBITDA Margin Guidance: iRhythm raised its full-year adjusted EBITDA margin guidance to 8.25% to 8.75% of revenues. This includes absorption of acquired IPR&D expenses, tariff impacts, and FDA remediation expenses.
Free Cash Flow: The company expects to be slightly free cash flow positive for full-year 2025, marking a significant milestone in its financial performance.
Future Growth and Investments: iRhythm plans to continue investing in growth initiatives, infrastructure scalability, and next-generation technology platforms to sustain profitable growth into 2026 and beyond.
The selected topic was not discussed during the call.
The earnings call reflects strong financial performance with improved operational efficiency and positive free cash flow, despite minor uncertainties in FDA timelines. Raised revenue guidance and optimistic growth in core and innovative channels, combined with strategic investments in innovation and market expansion, indicate a positive outlook. However, management's lack of clarity on some future plans tempers the sentiment slightly, but overall, positive elements outweigh the negatives, suggesting a positive stock price reaction.
The earnings call indicates strong revenue growth, increased market penetration, and raised guidance for 2025. Despite some concerns about seasonality and cautious guidance, the company's strategic partnerships and product integration with Epic are driving significant growth. The Q&A reveals optimism about sustainable reorder rates and market share expansion. The positive revenue outlook and strategic developments suggest a positive stock price movement, especially given the company's market cap, which allows for a more pronounced reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
